The European Commission's CORDIS platform has published a Results in Brief for NeoGiANT, an EU Horizon 2020 project that converts winery waste into livestock health solutions.

The result matters because it targets two pressures at once: the wine industry needs outlets for its by-products, and livestock producers need tools that reduce reliance on conventional treatments. NeoGiANT sits at that intersection. The project's name — a play on "neo" and "giant" framing next-generation natural compounds — signals its premise: extract value from material the winery sector currently discards.

What does the project actually do?

According to the CORDIS Results in Brief, NeoGiANT develops bioactive compounds from winery waste and tests them as health-supporting inputs for farmed animals. The platform piece is short, as Results in Brief entries are. It summarizes the work package rather than the underlying studies.

Winery waste, chiefly grape pomace and related by-products, carries a high load of plant polyphenols. Those molecules are the working material. The project processes them into forms that livestock producers can use in animal health programs.

The mechanism is straightforward. Plant-derived compounds with antioxidant and antimicrobial activity can support animal health directly. They can also preserve feed or improve gut function. Either way, the winery stream supplies the raw material, and the livestock sector supplies the application.

Why should veterinarians watch this?

For food-animal practitioners, the angle is practical. Producers under pressure to cut antibiotic use are actively sourcing alternatives. A validated, standardized by-product extract would give nutritionists and veterinarians a defined input rather than a supplement of variable composition.

The regulatory pathway matters as much as the science. Any grape-derived product marketed in the EU with health claims for food-producing animals falls under EFSA and EMA scrutiny, depending on whether regulators classify it as a feed additive or a veterinary product. The Results in Brief does not specify the regulatory status NeoGiANT is pursuing, so practitioners should treat this as a research-stage development until a dossier moves forward.

Companion-animal implications are absent from the source summary. Public-health implications are indirect: reducing antibiotic use in livestock slows resistance pressure, which is the stated policy driver behind much of Horizon 2020's animal-health funding.

How solid is the evidence?

The CORDIS Results in Brief format summarizes completed project work. It does not publish sample sizes, trial designs, or effect sizes, and those details are not in the source material for this story. Veterinarians evaluating the claims should look to the peer-reviewed outputs listed on the project's own publication record, where study design and species data would appear.

What the brief does establish is that the European Commission judged the project worth summarizing as a completed result. That is a curation signal, not a clinical endorsement.

What changes at the farm gate?

Right now, nothing. No product named in the brief carries market authorization from EMA or EFSA on the strength of this project alone. Producers may already buy grape-extract feed supplements from other suppliers; NeoGiANT's contribution is the targeted development pipeline from a specific waste stream.

If the project's compounds reach authorization, the practice-level change would appear first in feed formulation and herd health protocols, where veterinarians already advise on additive choices.

The project's next step, per the Results in Brief platform, is dissemination and exploitation of its outcomes — the standard route by which H2020 results move toward commercial or regulatory uptake.